Fresenius Kabi to invest $250 million in US manufacturing expansion

Germany-headquartered Fresenius Kabi says it plans to invest around $250 million over 10 years to expand the company’s Melrose Park site which manufactures generic, sterile injectable pharmaceuticals used in hospitals and clinics throughout the USA.

The expansion of the current Melrose Park site into a manufacturing campus is a multi-stage, multi-year project with ground breaking planned for 2017 and final project completion in 2026.

“We are creating a state-of-the-art pharmaceutical manufacturing campus that will be a showcase for our company and the production of injectable generic medicines,” said Steven Nowicki, senior vice president of global operations for North America, Pharmaceuticals Division at Fresenius Kabi. The company operates more than 70 manufacturing sites across the globe and the Melrose Park location will be one of its largest.